Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2023-12-13 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Voting Rights and Shares Capital of the Company
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY" and provides a table detailing the 'Number of Shares Outstanding' and 'Total number of voting rights' as of a specific date (November 30, 2023). It cites French Commercial Code articles (L.233-8 II) and the French Financial Markets Authority (AMF) regulations regarding the publication of total voting rights. This type of periodic disclosure, focusing solely on the total share count and voting rights, aligns best with the definition of a filing related to capital structure or a specific regulatory disclosure concerning share ownership/rights. While it is a regulatory announcement, the specific nature of reporting total voting rights makes it distinct from a general 'RNS'. It is not a dividend announcement (DIV), director dealing (DIRS), or a major shareholding notification (MRQ) which usually reports changes by specific entities crossing thresholds. Since it is a periodic update on the total capital structure and voting rights, it fits best under Capital/Financing Update (CAP) or potentially a specific regulatory filing. Given the options, 'CAP' covers changes to capital structure, and this is a mandatory disclosure of the current capital structure and voting rights. However, looking closely at the definitions, there is no perfect fit for a 'Total Voting Rights' disclosure. It is a regulatory disclosure about the capital base. Since it is a mandatory, periodic disclosure about the capital base, 'CAP' is a strong candidate. Alternatively, since it is a mandatory regulatory disclosure that doesn't fit other specific categories, 'RNS' (Regulatory Filings) is the fallback. Given the content is purely about the total number of shares and voting rights, which is a fundamental aspect of capital structure, I will classify it as CAP, as it is a direct update on the capital base, although RNS is also plausible if CAP is interpreted too narrowly as only fundraising events.
2023-12-13 English
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of November 30, 2023. This type of regular disclosure concerning the total share capital and voting rights is a specific regulatory requirement in France. While it relates to share capital, it is not a general capital change announcement (SHA) or a transaction in own shares (POS), but rather a mandatory periodic disclosure of the current structure. This fits best under the general 'Regulatory Filings' (RNS) category as a specific periodic regulatory update, although it is closely related to share structure. Given the options, and since it is a mandatory, periodic disclosure of share structure rather than a specific transaction or a comprehensive report, RNS is the most appropriate general regulatory filing category, although it is highly specific information. If a more specific code existed for 'Share Capital Disclosure', that would be chosen. Since it is a formal, mandated disclosure, RNS is the best fit among the provided codes, as it is a regulatory announcement.
2023-12-13 French
NANOBIOTIX ANNONCE LA CLÔTURE DE L'INVESTISSEMENT RESTANT DE 4,8 MILLIONS DE DOLLARS DE JOHNSON & JOHNSON INNOVATION - JJDC, INC.
Share Issue/Capital Change Classification · 99% confidence The document is a press release ("COMMUNIQUÉ DE PRESSE") dated December 4, 2023, announcing the closing of a remaining investment tranche of $4.8 million from Johnson & Johnson Innovation - JJDC, Inc. This transaction involves the issuance of new ordinary shares in the form of American Depositary Shares (ADSs) via a capital increase. The core subject is a financing activity, specifically the completion of a previously announced equity placement, which directly impacts the company's capital structure and cash position. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it details a specific corporate finance event.
2023-12-04 French
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing the closing of a capital raise (share issuance) by Nanobiotix. It details the number of shares issued, the price, the impact on share capital/dilution, and the intended use of proceeds. This falls under the category of share issuance and capital changes.
2023-12-04 English
Franchissement de seuil et déclaration d'intention
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de franchissement de seuil et déclaration d'intention" (Declaration of crossing a threshold and declaration of intent) and explicitly references French commercial code articles (L. 233-7) and AMF (Autorité des marchés financiers) regulations. It details a significant shareholder (Johnson & Johnson Innovation – JJDC, Inc.) crossing the 10% voting rights threshold in NANOBIOTIX. This type of filing, reporting changes in significant share ownership or insider transactions, aligns best with the 'Major Shareholding Notification' category (MRQ) or potentially 'Director's Dealing' (DIRS) if the entity were a director, but since it's a major shareholder notification regarding crossing a threshold, MRQ is the most precise fit among the provided options. It is not an earnings release, annual report, or proxy statement.
2023-11-30 French
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
Earnings Release Classification · 98% confidence The document is explicitly titled "NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update" and contains key financial metrics, operational highlights, pipeline status, and details about a conference call scheduled to discuss these results. This structure—providing key performance indicators and financial figures for a specific fiscal period (Q3 2023) but presented as a press release summary rather than the full, detailed regulatory filing—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim/Quarterly Report (IR), as it focuses on highlights and announces the call where details will be discussed. The document mentions the upcoming conference call and webcast, which is typical for an ER. Q3 2023
2023-11-13 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.